LCMS
Další informace
WebinářeO násKontaktujte násPodmínky užití
LabRulez s.r.o. Všechna práva vyhrazena. Obsah dostupný pod licencí CC BY-SA 4.0 Uveďte původ-Zachovejte licenci.
Pořadatel
Agilent Technologies
Agilent Technologies
Analytičtí vědci a kliničtí výzkumníci po celém světě spoléhají na Agilent a na to, že jim pomůže splnit i ty nejsložitější požadavky v laboratoři. Naše přístroje, software, služby a spotřební materiál řeší celou škálu potřeb ve Vaší laboratoři.
Tagy
LC/MS
LinkedIn Logo

High-throughput LC-MS analysis to systematically map gut microbiome drug metabolism

ZÁZNAM | Proběhlo St, 21.7.2021
Náš webinář se zabývá tím, jak můžeme pomocí vysoce výkonné LC-MS analýzy systematicky mapovat schopnost střevní mikrobioty metabolizovat léky.
Přejít na webinář
Pixabay/Remaztered Studio: High-throughput LC-MS analysis to systematically map gut microbiome drug metabolism
Pixabay/Remaztered Studio: High-throughput LC-MS analysis to systematically map gut microbiome drug metabolism

Individuals vary widely in their drug responses, which can be dangerous and expensive due to significant treatment delays and adverse effects. Growing evidence implicates the gut microbiome in this variability, however the molecular mechanisms remain mostly unknown.

To systematically map the drug metabolizing capacity of the gut microbiota and assess its potential contribution to drug metabolism, the speaker measured the ability of 76 diverse human gut bacteria to metabolize each of 271 oral drugs. They found that two thirds of these drugs are chemically modified by at least one of the tested microbes.

Through combination of high-throughput bacterial genetics with mass spectrometry-based metabolomics, the speaker systematically identified drug-metabolizing microbial enzymes. These proteins better explain the drug metabolizing capacity of bacterial strains than their phylogenetic classification.

The speaker further demonstrated that the abundance of homologs of these proteins predict the capacity of complete human gut communities to metabolize the targeted drugs. These causal links between microbiota gene content and metabolic activities connect inter-individual microbiome variability to interpersonal differences in drug metabolism, which has translatable potential on medical therapy and drug development across multiple disease indications.

Learn how to:

  • Employ high-throughput LC-MS analysis to map gut microbial metabolism
  • Combine bacterial genetics with high-throughput LC-MS analysis to identify metabolic enzymes in the gut microbiome
  • Integrate in vitro drug metabolism of gut bacteria, genomic information, and metagenomic data.

Presenter: Dr. Michael Zimmermann (Group Leader, European Molecular Biology Laboratory (EMBL), Heidelberg)

Michael Zimmermann, Ph.D., is a group leader at the European Molecular Biology Laboratory (EMBL), Heidelberg, Germany. His group combines high-throughput mass spectrometry, bacterial genetics, mouse models and computational approaches to investigate the metabolic interactions within the microbiome and between the microbiome and its host.

Moderator: Sarah Hiddleston (Science Journalist, Nature Research for Nature Middle East)

Sarah Hiddleston is freelance journalist working with Nature Research for Nature Middle East since 2015. Previously, Sarah worked for a decade in Madras (Chennai), India, specialising in health, pharmaceutical and environmental stories. Sarah holds an MA in Investigative Journalism from City University London, an MSc in Political Theory from the London School of Economics, and an undergraduate degree in History from the University of Cambridge, UK.

Agilent Technologies
LinkedIn Logo
 

Mohlo by Vás zajímat

Simultaneous Quantitation and Discovery analysis: Combining targeted and untargeted metabolomics on Orbitrap mass spectrometers

Aplikace
| 2026 | Thermo Fisher Scientific
Instrumentace
LC/MS, LC/MS/MS, LC/Orbitrap, LC/HRMS
Výrobce
Thermo Fisher Scientific
Zaměření
Metabolomika

Analysis of Per- and Polyfluoroalkyl Substances (PFAS) in Wastewater

Aplikace
| 2026 | Agilent Technologies
Instrumentace
LC/MS, LC/MS/MS, LC/QQQ
Výrobce
Agilent Technologies
Zaměření
Životní prostředí

Non-Targeted Screening of Biosolids with the Xevo™ MRT Mass Spectrometer Reveals New Isoforms of PFAS

Aplikace
| 2026 | Waters
Instrumentace
LC/MS, LC/MS/MS, LC/TOF, LC/HRMS
Výrobce
Waters
Zaměření
Životní prostředí

High Resolution Characterization of Lipid Nanoparticles Using the Xevo™ Charge Detection Mass Spectrometry (CDMS) Instrument - Single Particle Mass Analysis of Intact LNP-mRNA Formulations

Aplikace
| 2026 | Waters
Instrumentace
LC/MS, LC/MS/MS, LC/HRMS, Charakterizace částic, LC/IT
Výrobce
Waters
Zaměření
Lipidomika

Out-of-the-box workflow for PFAS quantitation using a fullscan high-resolution approach with the Orbitrap Exploris EFOX Mass Detector

Aplikace
| 2025 | Thermo Fisher Scientific
Instrumentace
LC/MS, LC/MS/MS, LC/Orbitrap, LC/HRMS
Výrobce
Thermo Fisher Scientific
Zaměření
Životní prostředí
Další projekty
GCMS
ICPMS
Sledujte nás
FacebookX (Twitter)LinkedInYouTube
Další informace
WebinářeO násKontaktujte násPodmínky užití
LabRulez s.r.o. Všechna práva vyhrazena. Obsah dostupný pod licencí CC BY-SA 4.0 Uveďte původ-Zachovejte licenci.